Editor's Corner: Who are the most influential people in biopharma today? We're asking you

Jirsak/iStock

Once again, we at FiercePharma and FierceBiotech are putting together a list of the year’s most influential people in biopharma. And we want your help.

Using our online form, we’re asking you, our readers, to make nominations and help us decide who should be part of that group.

What do we mean by “influential,” exactly? We’re looking for people who are impacting their own companies and organizations, sure, but those also who are making a mark on the wider industry. When all is said and done, our aim is to have a list of trailblazers and trendsetters in 2017.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Of course, there’s no one particular way to do it. In the past, we’ve featured everyone from activist investors to science whizzes to cost watchdogs, from dealmaking geniuses to politicians to CEOs. Need a refresher? Here are our editions of the report from 2016, 2015, 2014, and 2013.

A few other guidelines as you make your recommendations: Feel free to submit as many nominees as you'd like, though you'll have to fill out a separate form for each. We’ll include someone who’s made the cut before, provided you can make the case that there’s a new, timely reason they should be featured this year in particular. And we’ll be closing the polls one week from today, on Tuesday, Feb. 14.

With that, nominate away. We look forward to reading your submissions. — Carly Helfand (email | Twitter)

Access the nomination form >>

Read more on

Suggested Articles

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.